This hypothesis was later supported by a pilot clinical trial in which patients with amnestic mild cognitive impairment (MCI) or mild to moderate AD were given insulin 20 IU or 40 IU intranasally (NCT00438568). The gene discussed is INS; the disease is Alzheimer disease.